Evolution of Pseudomonas aeruginosa type III secretion in cystic fibrosis: a paradigm of chronic infection

Translational Research

Volumn 152, Issue 6, 2008, Pages 257-264

  Jain, Manu ^a   Bar Meir, Maskit ^a   McColley, Susanna ^a   Cullina, Joanne ^a   Potter, Eileen ^a   Powers, Cathy ^a   Prickett, Michelle ^a   Seshadri, Roopa ^a   Jovanovic, Borko ^a   Petrocheilou, Argyri ^a   King, John D ^a   Hauser, Alan R ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; TOBRAMYCIN; VIRULENCE FACTOR;

ADOLESCENT; ADULT; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CYSTIC FIBROSIS; DATA ANALYSIS; DISEASE DURATION; DISEASE EXACERBATION; FEMALE; FORCED EXPIRATORY VOLUME; GRAM NEGATIVE INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR EVOLUTION; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN SECRETION; PSEUDOMONAS AERUGINOSA; SPIROMETRY; TYPE III SECRETION SYSTEM;

EID: 57149095876     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2008.10.003     Document Type: Article

References (31)

1. Rello J., Ausina V., Ricart M., Castella J., and Prats G. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 104 (1993) 1230-1235
2. Micek S.T., Kollef K.E., Reichley R.M., Roubinian N., and Kollef M.H. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother 51 (2007) 3568-3573
3. Rello J., Jubert P., Valles J., Artigas A., Rue M., and Niederman M.S. Evaluation of outcome for intubated patients with pneumonia due to Pseudomonas aeruginosa. Clin Infect Dis 23 (1996) 973-978
4. Feldman M., Bryan R., Rajan S., et al. Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection. Infect Immun 66 (1998) 43-51
5. Ohama M., Hiramatsu K., Miyajima Y., Kishi K., Nasu M., and Kadota J. Intratracheal immunization with pili protein protects against mortality associated with Pseudomonas aeruginosa pneumonia in mice. FEMS Immunol Med Microbiol 47 (2006) 107-115
6. Tateda K., Ishii Y., Horikawa M., et al. The Pseudomonas aeruginosa autoinducer N-3-oxododecanoyl homoserine lactone accelerates apoptosis in macrophages and neutrophils. Infect Immun 71 (2003) 5785-5793
7. O'Malley Y.Q., Abdalla M.Y., McCormick M.L., Reszka K.J., Denning G.M., and Britigan B.E. Subcellular localization of Pseudomonas pyocyanin cytotoxicity in human lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 284 (2003) L420-L430
8. Meyer J.M., Neely A., Stintzi A., Georges C., and Holder I.A. Pyoverdin is essential for virulence of Pseudomonas aeruginosa. Infect Immun 64 (1996) 518-523
9. Kurahashi K., Kajikawa O., Sawa T., et al. Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia. J Clin Invest 104 (1999) 743-750
10. Frank D.W. The exoenzyme S regulon of Pseudomonas aeruginosa. Mol Microbiol 26 (1997) 621-629
11. Roy-Burman A., Savel R.H., Racine S., et al. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 183 (2001) 1767-1774
12. Hauser A.R., Cobb E., Bodi M., et al. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med 30 (2002) 521-528
13. Feltman H., Schulert G., Khan S., Jain M., Peterson L., and Hauser A.R. Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology 147 (2001) 2659-2669
14. Barbieri J.T., and Sun J. Pseudomonas aeruginosa ExoS and ExoT. Rev Physiol Biochem Pharmacol 152 (2004) 79-92
15. Sato H., and Frank D.W. ExoU is a potent intracellular phospholipase. Mol Microbiol 53 (2004) 1279-1290
16. FitzSimmons S.C. The changing epidemiology of cystic fibrosis. J Pediatr 122 (1993) 1-9
17. Fegan M., Francis P., Hayward A.C., Davis G.H., and Fuerst J.A. Phenotypic conversion of Pseudomonas aeruginosa in cystic fibrosis. J Clin Microbiol 28 (1990) 1143-1146
18. Burns J.L., Gibson R.L., McNamara S., et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 183 (2001) 444-452
19. Smith E.E., Buckley D.G., Wu Z., et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A 103 (2006) 8487-8492
20. Gallant C.V., Raivio T.L., Olson J.C., Woods D.E., and Storey D.G. Pseudomonas aeruginosa cystic fibrosis clinical isolates produce exotoxin A with altered ADP-ribosyltransferase activity and cytotoxicity. Microbiology 146 (2000) 1891-1899
21. De Vos D., De Chial M., Cochez C., et al. Study of pyoverdine type and production by Pseudomonas aeruginosa isolated from cystic fibrosis patients: prevalence of type II pyoverdine isolates and accumulation of pyoverdine-negative mutations. Arch Microbiol 175 (2001) 384-388
22. Lee B., Haagensen J.A., Ciofu O., Andersen J.B., Hoiby N., and Molin S. Heterogeneity of biofilms formed by nonmucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J Clin Microbiol 43 (2005) 5247-5255
23. Luzar M.A., Thomassen M.J., and Montie T.C. Flagella and motility alterations in Pseudomonas aeruginosa strains from patients with cystic fibrosis: relationship to patient clinical condition. Infect Immun 50 (1985) 577-582
24. Romling U., Fiedler B., Bosshammer J., Walshaw M.J., Ledson M.J., and Hart C.A. Epidemiology of chronic Pseudomonas aeruginosa infections in cystic fibrosis. J Infect Dis 170 (1994) 1616-1621
25. Lechtzin N., John M., Irizarry R., Merlo C., Diette G.B., and Boyle M.P. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration 73 (2006) 27-33
26. Jain M., Ramirez D., Seshadri R., et al. Type III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with cystic fibrosis. J Clin Microbiol 42 (2004) 5229-5237
27. Kang P.J., Hauser A.R., Apodaca G., et al. Identification of Pseudomonas aeruginosa genes required for epithelial cell injury. Mol Microbiol 24 (1997) 1249-1262
28. Thompson Mr B.M., Sokol P.A., Lile J.D., and Iglewski B.H. Exoenzyme S: an ADP-ribosyltransferase produced by Pseudomonas Aeruginosa. In: Smulson M.S.T. (Ed). Novel ADP-ribosylation of regulatory enzymes and proteins (1980), Amsterdam, the Netherlands, Elsevier/North Holland Inc 425-433
29. Nguyen D., and Singh P.K. Evolving stealth: genetic adaptation of Pseudomonas aeruginosa during cystic fibrosis infections. Proc Natl Acad Sci U S A 103 (2006) 8305-8306
30. Schulert G.S., Feltman H., Rabin S.D., et al. Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia. J Infect Dis 188 (2003) 1695-1706
31. Imamura Y., Yanagihara K., Fukuda Y., et al. Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model. Eur Respir J 29 (2007) 965-968